Image du mois. Fibrodysplasie musculaire de l'artère rénale.Gach, Olivier ; Pierard, Luc ; Legrand, Victor ![]() in Revue Médicale de Liège (2004), 59(11), 624-5 Detailed reference viewed: 60 (2 ULg) Drug-eluting stents: meta-analysis in diabetic patients.Scheen, André ; Warzee, Fabian ; Legrand, Victor ![]() in European heart journal (2004), 25(23), 2167-82168-9 Detailed reference viewed: 10 (3 ULg) Angioplastie percutanee coronaire chez le patient diabetique Partie 1 : echecs relatifs lies a la restenose apres angioplastie simple.Warzee, Fabian ; Legrand, Victor ; Scheen, André ![]() in Revue Médicale de Liège (2004), 59(10), 584-90 Diabetes mellitus, essentially type 2 diabetes, is markedly associated with a high risk of cardiovascular diseases, especially coronary artery disease (CAD). Revascularization techniques, first coronary ... [more ▼] Diabetes mellitus, essentially type 2 diabetes, is markedly associated with a high risk of cardiovascular diseases, especially coronary artery disease (CAD). Revascularization techniques, first coronary artery bypass graft (CABG) and second percutaneous transluminal coronary angioplasty (PTCA), have drastically changed the management of patients with CAD. Unfortunately, overall results of such revascularization procedures are less impressive in diabetic patients than in nondiabetic subjects, because of a worse vascular bed due to a more diffuse disease including small vessels. The diabetic population is indeed characterized by higher rates of both post-CABG thrombosis and post-PTCA restenosis, as compared to the corresponding rates observed in a nondiabetic population. Such vascular complications result in a higher incidence of coronary events leading to greater morbidity and mortality in both the short (weeks-months) and long (years) term. The bad quality of blood glucose control appears to play a crucial role in the risk of restenosis and further complications. The use of endovascular stents, especially new drug-eluting stents reducing the risk of restenosis, may represent a new opportunity for the management of a high-risk population such as diabetic patients. [less ▲] Detailed reference viewed: 52 (1 ULg) Angioplastie percutanee coronaire chez le patient diabetique. Partie 2: Espoirs apportes par les protheses endovasculaires.Warzee, Fabian ; Legrand, Victor ; Scheen, André ![]() in Revue Médicale de Liège (2004), 59(11), 653-8 Coronary artery revascularization procedures provide less favourable results in diabetic patients than in non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated with ... [more ▼] Coronary artery revascularization procedures provide less favourable results in diabetic patients than in non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated with a higher rate of restenosis and recurrence of cardiac morbidity and death. In diabetic patients, PTCA should, if possible, be combined with a stent. Bare-stents allow to reduce approximately by half the risk of restenosis, but unfortunately their efficacy decreases as the vessel diameter decreases, a common finding among diabetic patients with angiopathy. ARTS ("Arterial Revascularization Therapy Study") recently showed that diabetic patients have a worse prognosis even when bare-stents are combined with PTCA as compared to non-diabetic subjects and as compared to diabetic patients treated with coronary artery bypass graft. These results open new perspectives in favour of the use of drug-eluting stents containing pharmacological agents capable of preventing restenosis. Such new stents might improve the management of diabetic patients with coronary heart disease. [less ▲] Detailed reference viewed: 28 (0 ULg) Angioplastie percutanee coronaire chez le patient diabetique. Partie 3: Nouvelles perspectives apportees par les stents enrobes.Warzee, Fabian ; Legrand, Victor ; Scheen, André ![]() in Revue Médicale de Liège (2004), 59(12), 711-6 Coronary revascularization procedures are associated with less favourable outcomes in diabetic patients as compared to non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is ... [more ▼] Coronary revascularization procedures are associated with less favourable outcomes in diabetic patients as compared to non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated with a high level of restenosis and recurrent cardiac morbidity and mortality. In diabetic patients, PTCA should ideally be combined with stents. Bare-metal stents reduce by almost half the risk of restenosis, but this favourable effect decreases with the vessel calibre, a common finding in diabetic patients. Drug-eluting stents containing pharmacological agents that can reduce the risk of restenosis (sirolimus, paclitaxel) provide better angiographic results, including in small coronary arteries, and this effect has been shown to be accompanied by significant reduction of both morbidity and mortality. Such preliminary results obtained in the general population (including around 20% of diabetic subjects) deserve further confirmation in a large clinical trial specifically devoted to diabetic patients. Drug-eluting stents may represent a major advance in the management of diabetic patients with coronary heart disease in the near future. [less ▲] Detailed reference viewed: 48 (2 ULg) L'etude clinique du mois. L'etude EUROPA: protection cardio-vasculaire avec le perindopril chez les patients avec coronaropathie stable.Scheen, André ; Legrand, Victor ![]() in Revue Médicale de Liège (2003), 58(11), 713-6 The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the angiotensin ... [more ▼] The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the angiotensin-converting-enzyme inhibitor perindopril reduces cardiovascular risk in a population with stable coronary heart disease and no apparent heart failure, whatever the associated cardiovascular risk. Patients were randomly assigned perindopril 8 mg once daily (n = 6110) or matching placebo (n = 6108). After a mean follow-up of 4.2 years, a relative risk reduction of 20% (95% CI 9-29, p = 0.0003) was observed in the combined primary endpoint (cardiovascular death, myocardial infarction, or cardiac arrest) in the group treated with perindopril as compared to placebo. About 50 patients needed to be treated for a period of 4 years to prevent one major cardiovascular event. This benefit was consistent in all predefined subgroups. According to these results, treatment with perindopril, on top of other preventive medications, should be considered in all patients with stable coronary heart disease. [less ▲] Detailed reference viewed: 56 (0 ULg) Periodontal condition in Belgian patients with acute or chronic heart diseaseGeerts, Sabine ; Charpentier, Joseph ; Albert, Adelin et alin Journal of Dental Research (2002, December), 81(Sp. Iss. B), 240-240 Detailed reference viewed: 15 (5 ULg) Systemic release of endotoxins induced by gentle mastication: Association with periodontitis severityGeerts, Sabine ; Nys, Monique ; De Mol, Patrick et alin Journal of Dental Research (2002, December), 81(Sp. Iss. B), 235-235 Detailed reference viewed: 18 (4 ULg) Apports des troponines au diagnostic et traitement des cardiopathies ischémiquesChapelle, Jean-Paul ; Legrand, Victor ![]() Conference (2002, June 26) Detailed reference viewed: 9 (0 ULg) Association between lipoprotein (A) and cardiac troponins in PTCA patientsLutteri, Laurence ; Legrand, Victor ; et alPoster (2001, May) Detailed reference viewed: 3 (0 ULg) Relationship between lipoprotein (a) and cardiac troponins in PTCA patientsLutteri, Laurence ; Legrand, Victor ; et alin Acta Clinica Belgica (2001), 56 Detailed reference viewed: 3 (0 ULg) Cardiac troponin I and T concentrations are related to plasma lipoprotein (a) levels in PTCA patientsChapelle, Jean-Paul ; Legrand, Victor ; Lutteri, Laurence et alin European Heart Journal (2001), 22 Detailed reference viewed: 2 (0 ULg) Association between lipoprotein (A) and cardiac troponins in PTCA patientsLutteri, Laurence ; Legrand, Victor ; et alin Clinical Chemistry & Laboratory Medicine (2001), 39(suppl), 278 Detailed reference viewed: 1 (0 ULg) Marqueurs cardiaques: stratégie d'utilisation et d'interprétationChapelle, Jean-Paul ; Legrand, Victor ![]() Conference (2000, October) Detailed reference viewed: 3 (0 ULg) Hyperhomocysteinemia and cardiovascular risk in PTCA patientsLutteri, Laurence ; Chapelle, Jean-Paul ; Legrand, Victor et alPoster (2000, January 22) Detailed reference viewed: 1 (0 ULg) Prognostic significance of increased baseline plasma troponin I levels in PTCA patientsChapelle, Jean-Paul ; Biessaux, Yves ; Legrand, Victor et alin Heart (2000), 83(suppl. II), 24 Detailed reference viewed: 1 (0 ULg) Prognostic significance of increased baseline plasma troponin I levels in PTCA patientsChapelle, Jean-Paul ; Legrand, Victor ; in Clinical Chemistry (2000), 46(suppl), 82 Detailed reference viewed: 2 (0 ULg) Inflammatory response to coronary angioplasty: determinants and clinical applicationsBiessaux, Yves ; Martinez, Christophe ; Chapelle, Jean-Paul et alPoster (1999, December 01) Detailed reference viewed: 9 (1 ULg) Marqueurs cardiaques : CK-MB ou troponines?Chapelle, Jean-Paul ; Legrand, Victor ![]() Conference (1999, October) Detailed reference viewed: 4 (0 ULg) |
||